MBX (MBX Biosciences) Debt-to-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences Debt-to-Asset?

MBX Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.17 Mil. MBX Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.04 Mil. MBX Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $282.40 Mil. MBX Biosciences's debt to asset for the quarter that ended in Sep. 2024 was 0.00.

MBX Biosciences Debt-to-Asset Historical Data

The historical data trend for MBX Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MBX Biosciences Debt-to-Asset Chart

MBX Biosciences Annual Data

Trend

Dec22

Dec23

Debt-to-Asset

0.01

MBX Biosciences Quarterly Data
	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of MBX Biosciences's Debt-to-Asset

For the Biotechnology subindustry, MBX Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MBX Biosciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MBX Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where MBX Biosciences's Debt-to-Asset falls into.

MBX Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

MBX Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.153	+	0.171)	/	84.18
	=	0.00

MBX Biosciences's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.166	+	0.044)	/	282.4
	=	0.00

MBX Biosciences (NAS:MBX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

MBX Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of MBX Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

MBX Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032

Website

https://www.mbxbio.com

MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.